Nifty 50
- Apollo Hospitals₹9,120382.00 (4.37%)
- Titan Company₹4,574-126.00 (-2.68%)
- Max Healthcare₹1,074.7034.05 (3.27%)
- Tata Steel₹177.08-3.81 (-2.11%)
- TCS₹2,400.8058.10 (2.48%)
- Shriram Finance₹954.30-19.00 (-1.95%)
- Tech Mahindra₹1,764.8041.80 (2.43%)
- JSW Steel₹1,311.50-25.30 (-1.89%)
- Maruti Suzuki₹13,915326.00 (2.40%)
- Hindustan Unilever₹2,044.90-29.30 (-1.41%)
- Infosys₹1,10917.10 (1.57%)
- BSE₹3,712-53.00 (-1.41%)
- Axis Bank₹1,399.4018.60 (1.35%)
- Grasim Industries₹3,068.20-42.90 (-1.38%)
- HCL Technologies₹1,348.8015.90 (1.19%)
- Jio Financial ₹224.20-2.60 (-1.15%)
- HDFC Bank₹831.109.30 (1.13%)
- Reliance Industries₹1,360-15.60 (-1.13%)
- UltraTech Cement₹12,700140.00 (1.11%)
- NTPC₹321.80-3.20 (-0.98%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Natco Pharma Receives Voluntary Action Indicated Status for Visakhapatnam Facility From USFDA; Shares Fall 0.21%
Authored By HDFC SKY | Published at: Nov 20, 2026 10:41 AM IST
Natco Pharma Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam. The regulator classified the inspection as Voluntary Action Indicated (VAI), following four observations issued during the August 2026 inspection. Natco Pharma shares traded marginally lower during morning trading on November 20, 2026.

Open Free Demat Account
Mumbai, November 20: Natco Pharma Limited has announced that it has received an Establishment Inspection Report from the USFDA for its Finished Dosage Formulations manufacturing facility in Parawada, Visakhapatnam, Andhra Pradesh. The regulatory agency has classified the inspection as Voluntary Action Indicated, following an inspection conducted between August 17 and August 21, 2026. The company disclosed the development to stock exchanges on November 20. Natco Pharma shares traded around ₹820 during Friday’s morning session, marginally below the previous closing price.
USFDA Issues EIR With VAI Classification for Natco Pharma’s FDF Unit
According to the company’s November 20 regulatory filing, the USFDA conducted an inspection at Natco Pharma’s Finished Dosage Formulations facility in Parawada, Visakhapatnam, from August 17 to August 21, 2026. Following the inspection, the regulator issued four observations through Form 483, which the company had disclosed on August 21. Natco Pharma has now received the Establishment Inspection Report, with the inspection classified as Voluntary Action Indicated. A VAI classification indicates that the regulator identified objectionable conditions or practices, but the findings do not currently warrant official regulatory enforcement action. The classification differs from No Action Indicated (NAI), which generally means that no objectionable conditions were identified, and Official Action Indicated (OAI), which indicates that regulatory or administrative action may be warranted. The EIR provides clarity on the regulatory status of the August inspection. However, the VAI classification does not mean that all observations have been cleared without corrective action. The announcement is relevant to Natco Pharma’s US-facing manufacturing operations, as regulatory compliance is an important consideration for pharmaceutical companies supplying the American market.
Stock Market Snapshot
Natco Pharma share price were trading at approximately ₹820.20 on Friday, November 20, 2026, down ₹1.75 or 0.21% from the previous NSE closing price of ₹821.95 on November 19. The stock initially moved above ₹826 during early trading, touching approximately ₹827 before easing towards ₹822. Shares subsequently fluctuated between ₹822 and ₹827 before declining below the previous closing price around 9:47 AM. The stock touched approximately ₹818.20 before recovering slightly towards ₹820.20. The supplied chart extends to approximately 9:55 AM IST. The quoted price and percentage movement are approximate because the chart does not display an exact last-traded timestamp. The USFDA inspection update coincided with the morning trading session. However, no independently verified evidence establishes the regulatory development as the direct reason for the stock’s movement.

About Natco Pharma
Natco Pharma Limited is a Hyderabad-based pharmaceutical company engaged in the development, manufacturing and marketing of finished dosage formulations, active pharmaceutical ingredients and specialty medicines. The company has a presence in India and international markets, including the United States. Its portfolio includes oncology medicines, specialty pharmaceuticals and products across other therapeutic categories.
Conclusion
Natco Pharma has received an Establishment Inspection Report from the USFDA for its Visakhapatnam formulations facility, with the inspection classified as Voluntary Action Indicated. The classification follows four observations issued during the August 2026 inspection and indicates that official regulatory enforcement action is not currently warranted. Natco Pharma shares traded marginally lower during morning trading on November 20, while the regulatory update provides greater clarity on the inspection’s outcome.
Source:
- https://www.nseindia.in/get-quote/equity/NATCOPHARM/Natco-Pharma-Limited
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More NATCOPHARM News
Open Free Demat Account
₹814.05
By signing up I certify terms, conditions & privacy policy

Join Us
Add as preferred source on Google


















